Clinical Trial Update: Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial updates long-term safety and efficacy of tirabrutinib in adults with relapsed/refractory B-cell malignancies; study completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• Tirabrutinib (tirabrutinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Relapsed/Refractory B-cell Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2022-03-24